Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05938322

Ketogenic Diet Compliance in Patients Undergoing Radiotherapy for Pelvic Cancers

Patients with locally advanced non-metastatic adenocarcinoma of the rectum undergoing chemoradiation therapy will be assigned to 2 groups:

* the intervention group will be prescribed an individualized ketogenic eating plan to be followed throughout the treatment period * the control group will be prescribed a diet therapy plan treatment following the international guidelines of clinical nutrition, also to be followed during treatment

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Fondazione Policlinico Universitario Agostino Gemelli, IRCCS

Rome, Italy

Location status: Recruiting

About this study

Some days before the start of radiotherapy there will be the first visit in which patients will be enrolled and placed in one of the following two groups:

  • The intervention group (KD) will be prescribed a ketogenic diet therapy plan characterized by the following composition: carbohydrates < 30g/day, 1.2g-1.5g protein/kg/day and lipids > 65%.
  • The control group (SD) will be prescribed a nutrition plan based on the Mediterranean diet model according to ESPEN guidelines (carbohydrates 45-55%, protein 15-20% and lipids 30-35%) There will then be two additional follow-ups for patients: one during the period of therapy and one at the end of therapy.

Compliance with diet therapy treatment (SD vs. KD) will be assessed by analysis of a food diary that the patient will be asked to complete.

During follow-ups it will be assessed:

  • BMI and body composition (by bioimpedance analysis)
  • Muscle strength and physical performance (by hand grip test and sit-to-stand test) Compliance with and toxicity of radiochemotherapy treatment will be assessed at the radiochemotherapy visits (3 visits during treatment)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologic confirmation of rectal adenocarcinoma
  • Locally advanced rectal cancer
  • Patients undergoing neoadjuvant radiotherapy treatment
  • Signature of informed consent to the processing of personal data

Exclusion criteria

  • Severely malnourished patients according to GLIM (Global Leadership Initiative on Malnutrition) criteria
  • Patients treated for palliative purposes
  • Patients with metastatic disease
  • Diabetes mellitus
  • Pregnancy or lactation
  • Significant food allergies that would make the person unable to consume the food provided
  • Refusal to participate in the proposed clinical trial

Treatment and study plan

Ketogenic diet

Other

In the group of intervention is prescribed a ketogenic diet plan characterized by the following composition: carbohydrates < 30g/day, 1.2g-1.5g protein/kg/day and lipids > 65%.

This diet will be followed during the period of treatment with chemo-radiotherapy (5 weeks)

Standard Diet

Other

The control group (SD) will follow the Mediterranean diet pattern based on ESPEN guidelines (carbohydrates 45-55%, protein 15-20% and lipids 30-35%).

Primary outcomes

  1. Adherence to the ketogenic diet

    Time frame: 2 months

    The primary objective is to assess the adherence to the diet therapy treatment plan (SD vs. KD). It will be verified through a food diary that will be given to the patient during the first visit.

    The patients will fill out the questionnaire and return it at future visits.

Secondary outcomes

  1. Assessment of fat mass (FM) in the group of patients on ketogenic diet (KD) compared with the control group

    Time frame: 2 months

    The assessment will be carried out through the use of an impedance analysis (BIA)

  2. Evaluation of maintenance of metabolically active mass (BCM) in the group of patients on ketogenic diet (KD) compared with the control group

    Time frame: 2 months

    The assessment will be carried out through the use of an impedance analysis (BIA)

  3. Investigate the impact of BCM maintenance on metabolic, inflammatory, hematologic and endocrine response

    Time frame: 2 months

    The assessment will be carried out through blood test analysis

  4. Evaluation of the correlation between ketogenic diet (KD) and metabolic, inflammatory, hematologic and endocrine response

    Time frame: 2 months

    The assessment will be carried out through blood test analysis

  5. Evaluation of the tolerability to the treatment

    Time frame: 2 months

    Radiotherapy interruptions will be evaluated

  6. Evaluation of the response to the treatment

    Time frame: 2 months

    The assessment will be carried out through pelvic MRI analysis, clinical evaluation, and pathological response

  7. Investigate indices of quality of life

    Time frame: 2 months

    Investigating patients' quality of life through questionnaires administered at the beginning and at the end of treatments. The questionnaires used are EORT ( European Organisation for Research and Treatment of Cancer) QLQ (quality of life questionnaire)-30, QLQ - CR29 and CAX-24 (cancer cachexia-specific questionnaire), and PRT-20 (quality of life questionnaire for proctitis).

Study contacts

Contact information is provided by the study sponsor or research team.

Maria Cristina Mele, MD

CONTACT

[email protected]

00390630156772

Sponsors and collaborators

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Other

Registry information

Official study title

Compliance With Ketogenic Diet in Patients Undergoing Radiotherapy for Pelvic Cancers: a Prospective, Randomized, Mono-centric Study

Acronym: KOMPARC

Important dates

Study start
2024
Primary completion
2026
Study completion
2027
First posted
Jul 10, 2023
Registry last updated
Sep 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.